Kiniksa Pharmaceuticals International

Commented by Nico Popp on November 9th, 2026 | 23:05 CET

Billion-dollar opportunity in cardiac therapy: Cardiol Therapeutics, Kiniksa and Novo Nordisk

• Pericarditis
• Cardiovascular diseases
• Biotech

Created and Published on Behalf of Cardiol Therapeutics

The treatment of inflammatory heart diseases is becoming one of the most lucrative segments of the pharmaceutical industry. The only drug approved to date for recurrent pericarditis is expected to exceed USD 1 billion in revenue this year. While established industry heavyweights generate enormous revenues from injectable biologics, emerging biotechnology companies are preparing the next stage of development. The focus is on the search for oral therapies intended to open up access to treatment for a much broader patient population.

Commented by Stefan Feulner on October 20th, 2026 | 05:23 CEST

AstraZeneca, Cardiol Therapeutics, Kiniksa – New hope for heart patients

• Biotechnology

Cardiovascular diseases remain among the greatest medical challenges worldwide. While established pharmaceutical groups invest billions in new active ingredients and artificial intelligence, specialised biotech companies are developing targeted therapies for conditions that have so far been difficult to treat, such as recurrent pericarditis. Patients often suffer from painful relapses and require long-term treatment. New medicines could fundamentally change how these conditions are managed. For investors, this brings into focus companies that already market approved products or are awaiting pivotal clinical trial results.